Stocks that outperform the market usually share key traits such as rising sales, expanding margins, and increasing returns on capital. The select few that ca...
Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Natera (NASDAQ:NTRA) and its ...
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Not...
What Happened? Shares of genetic testing company Natera (NASDAQ:NTRA). jumped 7.7% in the morning session after the company announced its Signatera test rece...
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory de...
A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion o...
Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new are...
Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. Howe...
Natera’s first quarter was marked by robust top-line growth and higher-than-expected sales volumes, but the market responded negatively due to a wider-than-a...
What Happened? Shares of genetic testing company Natera (NASDAQ:NTRA). fell 12.2% in the afternoon session after the company reported mixed first-quarter 202...
Natera (NASDAQ:NTRA) reported first-quarter 2026 revenue of $697 million, up 39% year over year, as the company delivered more than 1 million total units in a single quarter for the first time. Chief Executive Officer Steve Chapman said strong performance in women’s health and another record quarter
Genetic testing company Natera (NASDAQ:NTRA). reported Q1 CY2026 results topping the market’s revenue expectations, with sales up 38.8% year on year to $696....
Genetic testing company Natera (NASDAQ:NTRA). announced better-than-expected revenue in Q1 CY2026, with sales up 38.8% year on year to $696.6 million. Its GA...
Genetic testing company Natera (NASDAQ:NTRA). will be announcing earnings results this Thursday afternoon. Here’s what to expect. Natera beat analysts’ reven...
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...
Natera has had an impressive run over the past six months as its shares have beaten the S&P 500 by 6%. The stock now trades at $208.20, marking a 10.5% gain....
What Happened? A number of stocks jumped in the afternoon session after the reopening of the Strait of Hormuz signaled a cooling of global logistics and ener...
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff...
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f...
Even during a down period for the markets, Natera has gone against the grain, climbing to $211.23. Its shares have yielded a 22.1% return over the last six m...
